After the exclusion of clearly pathogenic truncating variants and the most frequent missense mutation I157T (whose frequency was not significantly different between our NHL patients and controls), all other relatively rare CHEK2 missense variants occurred more frequently in the patients’ group (Fig 1) and were also associated with an increased NHL risk (OR = 4.66; P = 0.045). Here, CHEK2 is linked to non-Hodgkin lymphoma.